Michael Crump
About
Michael Crump is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics.
According to data from OpenAlex, Michael Crump has authored 310 papers receiving a total of 9.8k indexed citations (citations by other indexed papers that have themselves been cited), including 198 papers in Pathology and Forensic Medicine, 160 papers in Oncology and 74 papers in Genetics. Recurrent topics in Michael Crump's work include Lymphoma Diagnosis and Treatment (194 papers), Chronic Lymphocytic Leukemia Research (67 papers) and Viral-associated cancers and disorders (58 papers). Michael Crump is often cited by papers focused on Lymphoma Diagnosis and Treatment (194 papers), Chronic Lymphocytic Leukemia Research (67 papers) and Viral-associated cancers and disorders (58 papers). Michael Crump collaborates with scholars based in Canada, United States and Italy. Michael Crump's co-authors include John Kuruvilla, Armand Keating, Melania Pintilie, Richard Tsang, Christian Gisselbrecht, David Hodgson, Mary Gospodarowicz, Woodrow Wells, Bertrand Coiffier and Annette E. Hay and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Michael Crump
292 papers receiving 9.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Michael Crump Canada | 49 | 5.6k | 5.3k | 2.4k | 1.6k | 1.5k | 310 | 9.8k | ||
| Ann S. LaCasce United States | 45 | 5.0k 0.9× | 3.5k 0.7× | 2.3k 1.0× | 1.2k 0.7× | 1.6k 1.1× | 208 | 7.7k | ||
| Jonathan W. Friedberg United States | 61 | 9.1k 1.6× | 6.5k 1.2× | 3.8k 1.6× | 1.5k 0.9× | 2.4k 1.6× | 393 | 12.7k | ||
| Michele Ghielmini Switzerland | 31 | 6.5k 1.2× | 4.5k 0.9× | 3.1k 1.3× | 932 0.6× | 1.2k 0.8× | 134 | 8.8k | ||
| Franco Cavalli Switzerland | 43 | 7.7k 1.4× | 5.0k 0.9× | 2.7k 1.1× | 1.5k 0.9× | 3.2k 2.2× | 190 | 11.6k | ||
| André Bosly Belgium | 45 | 5.8k 1.0× | 4.8k 0.9× | 2.4k 1.0× | 1.4k 0.9× | 1.9k 1.3× | 191 | 9.7k | ||
| Massimo Federico Italy | 45 | 8.0k 1.4× | 5.5k 1.0× | 2.1k 0.9× | 919 0.6× | 2.3k 1.6× | 288 | 12.0k | ||
| Catherine Thiéblemont France | 66 | 9.9k 1.8× | 7.0k 1.3× | 4.4k 1.8× | 2.0k 1.3× | 2.4k 1.6× | 420 | 14.3k | ||
| Won Seog Kim South Korea | 48 | 7.1k 1.3× | 6.3k 1.2× | 1.8k 0.8× | 1.3k 0.8× | 1.4k 0.9× | 462 | 10.8k | ||
| Brian K. Link United States | 47 | 7.3k 1.3× | 5.6k 1.1× | 3.5k 1.5× | 1.2k 0.8× | 1.1k 0.8× | 275 | 11.2k | ||
| Peter Mauch United States | 54 | 5.1k 0.9× | 3.7k 0.7× | 1.8k 0.7× | 1.0k 0.6× | 1.8k 1.2× | 242 | 10.8k |
Countries citing papers authored by Michael Crump
Since
Specialization
Citations
This map shows the geographic impact of Michael Crump's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Crump with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Crump more than expected).
Fields of papers citing papers by Michael Crump
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Michael Crump. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Crump. The network helps show where Michael Crump may publish in the future.
Co-authorship network of co-authors of Michael Crump
This figure shows the co-authorship network connecting the top 25 collaborators of Michael Crump. A scholar is included among the top collaborators of Michael Crump based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Crump. Michael Crump is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Gong, Inna Y., Michael Crump, Anca Prica, et al.. (2025). Outcomes and factors influencing survival in patients with diffuse large B-cell lymphoma: a population-based analysis. PubMed. 2(3). 100117–100117.
2.
Aoki, Tomohiro, Mary Salib, Michael Hong, et al.. (2025). Distinct characteristics and social determinants in adult T‐cell leukaemia/lymphoma patients at a tertiary cancer centre in Canada. British Journal of Haematology. 207(1). 132–140.
3.
Phillips, Tycel, Carmelo Carlo‐Stella, Franck Morschhauser, et al.. (2024). Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL): Updated analysis from a phase I/II study.. Journal of Clinical Oncology. 42(16_suppl). 7008–7008.
4.
Stewart, Douglas A., John Kuruvilla, David M. Lee, et al.. (2024). Canadian cancer trials group LY .17: A randomized phase II study evaluating novel salvage therapy pre‐autologous stem cell transplant in relapsed/refractory diffuse large B‐cell lymphoma—outcome of rituximab‐dose‐intensive cyclophosphamide, etoposide, cisplatin (R‐DICEP ) versus R‐GDP . British Journal of Haematology. 205(3). 881–890.
5.
Phillips, Tycel, Carmelo Carlo‐Stella, Franck Morschhauser, et al.. (2024). Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study. Journal of Clinical Oncology. 43(3). 318–328.
6.
Bhella, Sita, Robert Kridel, Vishal Kukreti, et al.. (2022). Clinical utility of interim CT scans in patients receiving chemoimmuntherapy for first line treatment of follicular lymphoma. Leukemia & lymphoma. 63(14). 3402–3408.
7.
Maganti, Manjula, Dmitry Rozenberg, Vishal Kukreti, et al.. (2022). Predicting the Risks of Aggressive-Intent Chemotherapy Toxicity in Older Patients With Lymphoma: A Prospective Observational Pilot Study. Clinical Lymphoma Myeloma & Leukemia. 22(8). e792–e803.
8.
Phillips, Tycel, Michael Dickinson, Franck Morschhauser, et al.. (2021). Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy. Blood. 138(Supplement 1). 130–130.
9.
Neelapu, Sattva S., Frederick L. Locke, Nancy L. Bartlett, et al.. (2021). Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. Blood Advances. 5(20). 4149–4155.
10.
Crump, Michael, Sattva S. Neelapu, Umar Farooq, et al.. (2017). Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 130(16). 1800–1808.
11.
Ogura, Michinori, Kensei Tobinai, Kiyohiko Hatake, et al.. (2016). Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma. Clinical Cancer Research. 22(19). 4807–4816.
12.
Zinzani, Pier Luigi, Max S. Topp, Sam Yuen, et al.. (2016). Phase 2 Study of Venetoclax Plus Rituximab or Randomized Ven Plus Bendamustine+Rituximab (BR) Versus BR in Patients with Relapsed/Refractory Follicular Lymphoma: Interim Data. Blood. 128(22). 617–617.
13.
Kuruvilla, John, David MacDonald, C. Tom Kouroukis, et al.. (2015). Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12. Blood. 126(6). 733–738.
14.
O’Connor, Owen A., Barbara Pro, Lauren Pinter‐Brown, et al.. (2011). Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study. Journal of Clinical Oncology. 29(9). 1182–1189.
15.
Bastianutto, Carlo, Asim Mian, Joseph D. Mocanu, et al.. (2007). Local Radiotherapy Induces Homing of Hematopoietic Stem Cells to the Irradiated Bone Marrow. Cancer Research. 67(21). 10112–10116.
16.
Ha, Chul S., L. Jeffrey Medeiros, Chusilp Charnsangavej, Michael Crump, & Mary Gospodarowicz. (2006). Oncodiagnosis panel: 2004 lymphoma. Radiographics. 26(2). 607–620.
17.
Mollee, Peter, Kyungchul Song, Armand Keating, Richard Tsang, & Michael Crump. (2002). Autologous stem cell transplantation (ASCT) for relapsed/refractory follicular large cell lymphoma (FLCL).. Blood. 100(11).
18.
Mackinnon, J., et al.. (1997). Febrile neutropenia after hematopoietic stem cell mobilization with chemotherapy and G-CSF does not affect collection of adequate numbers of CD34+ cells.. Blood. 90(10). 943–943.
19.
Keating, Armand, et al.. (1996). Treatment of acute myeloid leukemia (AML) at diagnosis in 99 unselected adults with high dose ARA-C (HIDAC) and mitoxantrone: Long-term follow-up.. Blood. 88(10). 833–833.
20.
Daniels, Geoff, et al.. (1990). Nutritional factors in the pathogenesis of proliferative enteritis and swine dysentery..
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Ann S. LaCasce Breakdown of academic impact, for papers by Jonathan W. Friedberg Breakdown of academic impact, for papers by Michele Ghielmini Breakdown of academic impact, for papers by Franco Cavalli Breakdown of academic impact, for papers by André Bosly Breakdown of academic impact, for papers by Massimo Federico Breakdown of academic impact, for papers by Catherine Thiéblemont Breakdown of academic impact, for papers by Won Seog Kim Breakdown of academic impact, for papers by Brian K. Link Breakdown of academic impact, for papers by Peter Mauch